Alzheimer's disease (AD) is a debilitating neurodegenerative disorder. Although peripheral immune cells have been implicated in the pathology of AD, the causal relationship between peripheral blood immune cells and AD remains to be fully elucidated.
Objective
To examine the association between peripheral blood immune cell phenotypes and AD, mediated by peripheral blood metabolite, a two-step Mendelian randomization (MR) analysis was performed.
Methods
Summary statistics were obtained from the two largest independent cohorts. We explored bidirectional univariable MR analysis to explore causal associations and assessed the mediated proportion of peripheral blood metabolite phenotypes.
Results
The proportion of IgD + CD38- B cells (Bm1) were found to increase the risk of AD in both the FinnGen database (p = 0.033) and the UK Biobank (p = 0.034). Conversely, hematopoietic stem cells were associated with a decreased risk of AD in the FinnGen database (p = 0.045) and the UK Biobank (p = 0.017). Mediation analysis revealed indirect effects of the proportion of Bm1 on AD through cysteine levels (β = 5 × 10−3), Acetylcarnitine (C2) to propionylcarnitine (C3) ratio (β = 4.5 × 10−3), and Gamma-glutamyl-alpha-lysine levels (β = 2.6 × 10−3), with mediated proportion of 19.4%, 16.9% and 9.6% of the total effect, respectively. Additionally, hematopoietic stem cells influenced AD through Glycolithocholate sulfate levels (β = 1.5 × 10−3), with a mediated proportion of 3.5%.
Conclusions
Our findings demonstrate that two peripheral blood immune cell phenotypes impact the risk of AD. These immune cells may influence AD through various peripheral blood metabolite, identifying potential intervention targets for individuals at risk.
KarikariTKAshtonNJBrinkmalmG, et al.Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol2022; 18: 400–418.
2.
PloweyEDBussiereTRajagovindanR, et al.Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol2022; 144: 143–153.
LiuYTanYZhangZ, et al.The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing. Transl Neurodegener2024; 13: 7.
5.
SpäniCSuterTDerungsR, et al.Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells. Acta Neuropathol Commun2015; 3: 71.
6.
SabatinoJJJr.PröbstelAKZamvilSS. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci2019; 20: 728–745.
7.
GuXDouMCaoB, et al.Peripheral level of CD33 and Alzheimer's disease: a bidirectional two-sample Mendelian randomization study. Transl Psychiatry2022; 12: 427.
8.
KimKWangXRagonnaudE, et al.Therapeutic B-cell depletion reverses progression of Alzheimer's disease. Nat Commun2021; 12: 2185.
9.
LvXZhouDGeB, et al.Association of folate metabolites and mitochondrial function in peripheral blood cells in Alzheimer's disease: a matched case-control study. J Alzheimers Dis2019; 70: 1133–1142.
10.
JorfiMParkJHallCK, et al.Infiltrating CD8(+) T cells exacerbate Alzheimer's disease pathology in a 3D human neuroimmune axis model. Nat Neurosci2023; 26: 1489–1504.
11.
FengWZhangYDingS, et al.B lymphocytes ameliorate Alzheimer's disease-like neuropathology via interleukin-35. Brain Behav Immun2023; 108: 16–31.
12.
FaniLGeorgakisMKIkramMA, et al.Circulating biomarkers of immunity and inflammation, risk of Alzheimer's disease, and hippocampal volume: a Mendelian randomization study. Transl Psychiatry2021; 11: 291.
13.
MishraPSilvaASharmaJ, et al.Rescue of Alzheimer's disease phenotype in a mouse model by transplantation of wild-type hematopoietic stem and progenitor cells. Cell Rep2023; 42: 112956.
14.
BakkerLKöhlerSEussenS, et al.Correlations between kynurenines in plasma and CSF, and their relation to markers of Alzheimer's disease pathology. Brain Behav Immun2023; 111: 312–319.
15.
FerrettiGSerafiniSAngiolilloA, et al.Advances in peripheral blood biomarkers of patients with Alzheimer's disease: moving closer to personalized therapies. Biomed Pharmacother2023; 165: 115094.
16.
RevegliaPPaolilloCAngiolilloA, et al.A targeted mass spectrometry approach to identify peripheral changes in metabolic pathways of patients with Alzheimer's disease. Int J Mol Sci2023; 24: 9736.
17.
YangJWuSYangJ, et al.Amyloid beta-correlated plasma metabolite dysregulation in Alzheimer's disease: an untargeted metabolism exploration using high-resolution mass spectrometry toward future clinical diagnosis. Front Aging Neurosci2023; 15: 1189659.
18.
ShrinivasanRWyatt-JohnsonSKBrutkiewiczRR. The MR1/MAIT cell axis in CNS diseases. Brain Behav Immun2024; 116: 321–328.
19.
SunYZhangHZhangX, et al.Promotion of astrocyte-neuron glutamate-glutamine shuttle by SCFA contributes to the alleviation of Alzheimer's disease. Redox Biol2023; 62: 102690.
20.
YinGGanYJiangH, et al.Direct quantification and visualization of homocysteine, cysteine, and glutathione in Alzheimer's and Parkinson's disease model tissues. Anal Chem2021; 93: 9878–9886.
21.
BurgessSThompsonSG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol2011; 40: 755–764.
22.
CarterARSandersonEHammertonG, et al.Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol2021; 36: 465–478.
23.
OrrùVSteriMSidoreC, et al.Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet2020; 52: 1036–1045.
24.
LarssonSCWoolfBGillD. Plasma caffeine levels and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomization study. Nutrients2022; 14: 1697.
25.
ChenYLuTPettersson-KymmerU, et al.Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat Genet2023; 55: 44–53.
26.
LeongVSYuJCastorK, et al.Associations of plasma glutamatergic metabolites with alpha desynchronization during cognitive interference and working memory tasks in asymptomatic Alzheimer's disease. Cells2024; 13: 970.
27.
DasSDewitNJacobsD, et al.A novel neurofilament light chain elisa validated in patients with Alzheimer's disease, frontotemporal dementia, and subjective cognitive decline, and the evaluation of candidate proteins for immunoassay calibration. Int J Mol Sci2022; 23: 970.
28.
LeeJHOstaleckiCObersteinT, et al.Alzheimer's disease protease-containing plasma extracellular vesicles transfer to the hippocampus via the choroid plexus. EBioMedicine2022; 77: 103903.
29.
LuoJThomassenJQBellenguezC, et al.Genetic associations between modifiable risk factors and Alzheimer disease. JAMA Netw Open2023; 6: e2313734.
30.
BurgessSDanielRMButterworthAS, et al.Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol2015; 44: 484–495.
31.
BurgessSDudbridgeFThompsonSG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med2016; 35: 1880–1906.
32.
BowdenJDel GrecoMFMinelliC, et al.A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med2017; 36: 1783–1802.
33.
BowdenJDavey SmithGBurgessS. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol2015; 44: 512–525.
34.
BowdenJDavey SmithGHaycockPC, et al.Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol2016; 40: 304–314.
35.
LinZPanIPanW. A practical problem with Egger regression in Mendelian randomization. PLoS Genet2022; 18: e1010166.
36.
FrancqBGCartiauxO. Delta method and bootstrap in linear mixed models to estimate a proportion when no event is observed: application to intralesional resection in bone tumor surgery. Stat Med2016; 35: 3563–3582.
37.
BohnhorstJBjørganMBThoenJE, et al.Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome. J Immunol2001; 167: 3610–3618.
38.
TianYLuYCaoY, et al.Identification of diagnostic signatures associated with immune infiltration in Alzheimer's disease by integrating bioinformatic analysis and machine-learning strategies. Front Aging Neurosci2022; 14: 919614.
39.
MuskardinTLWNiewoldTB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol2018; 14: 214–228.
40.
ZengFZhangJJinX, et al.Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases. J Cell Physiol2022; 237: 2796–2807.
41.
XiongLLXueLLDuRL, et al.Single-cell RNA sequencing reveals B cell-related molecular biomarkers for Alzheimer's disease. Exp Mol Med2021; 53: 1888–1901.
42.
XuHJiaJ. Single-cell RNA sequencing of peripheral blood reveals immune cell signatures in Alzheimer's disease. Front Immunol2021; 12: 645666.
43.
ParkJCNohJJangS, et al.Association of B cell profile and receptor repertoire with the progression of Alzheimer's disease. Cell Rep2022; 40: 111391.
44.
ShinJWLeeJKLeeJE, et al.Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell-derived factor-1α in an Alzheimer's disease mouse model. Stem Cells2011; 29: 1075–1089.
45.
ZhouWHeQZhangC, et al.BLOS2 Negatively regulates Notch signaling during neural and hematopoietic stem and progenitor cell development. Elife2016; 5: e18108.
46.
YooYNeumayerGShibuyaY, et al.A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer's disease. Cell Stem Cell2023; 30: 1043–1053.e1046.
47.
BouzidHBelkJAJanM, et al.Clonal hematopoiesis is associated with protection from Alzheimer's disease. Nat Med2023; 29: 1662–1670.
48.
MorrisMS. Homocysteine and Alzheimer's disease. Lancet Neurol2003; 2: 425–428.
49.
Sade YazdiDLaor Bar-YosefDAdsiH, et al.Homocysteine fibrillar assemblies display cross-talk with Alzheimer's disease β-amyloid polypeptide. Proc Natl Acad Sci U S A2021; 118: e2017575118.
50.
TripathiSJChakrabortySMillerE, et al.Hydrogen sulfide signalling in neurodegenerative diseases. Br J Pharmacol. Epub ahead of print 20 June 2023. DOI: https://doi.org/10.1111/bph.16170.
51.
YulugBAltayOLiX, et al.Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Transl Neurodegener2023; 12: 4.
52.
YanHFZouTTuoQZ, et al.Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther2021; 6: 49.
53.
CostaIBarbosaDJBenfeitoS, et al.Molecular mechanisms of ferroptosis and their involvement in brain diseases. Pharmacol Ther2023; 244: 108373.
54.
SunLGuoDJiaY, et al.Association between human blood metabolome and the risk of Alzheimer's disease. Ann Neurol2022; 92: 756–767.
55.
ZhaoZXingNHouL. Cerebrospinal fluid metabolites as potential biomarkers for epilepsy: insights from genome-wide association studies. Epilepsia Open2025; 10: 233–242.
56.
AndersenJVSchousboeAVerkhratskyA. Astrocyte energy and neurotransmitter metabolism in Alzheimer's disease: integration of the glutamate/GABA-glutamine cycle. Prog Neurobiol2022; 217: 102331.
57.
Vázquez-DuránDLOrtegaARodríguezA. Amino acid transporters proteins involved in the glutamate-glutamine cycle and their alterations in murine models of Alzheimer's disease. Mol Neurobiol2024; 61: 6077–6088.
58.
VarmaVROommenAMVarmaS, et al.Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med2018; 15: e1002482.
59.
HorgusluogluENeffRSongWM, et al.Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. Alzheimers Dement2022; 18: 1260–1278.
60.
SleimanPMGrantSF. Mendelian randomization in the era of genomewide association studies. Clin Chem2010; 56: 723–728.
61.
Davey SmithGHemaniG. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet2014; 23: R89–R98.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
